Proton pump inhibitors and fracture risk. The HUNT study, Norway
Proton pump inhibitors (PPIs) have been linked to increased risk of fracture; the data have, however, been diverging. We did not find any increased risk of fractures among users of PPIs in a Norwegian population of 15,017 women and 13,241 men aged 50–85 years with detailed information about lifestyle and comorbidity.
Proton pump inhibitors (PPIs) are widely prescribed and have been linked to increased risk of fracture.
We used data from the Nord-Trøndelag Health Study (HUNT3), The Fracture registry in Nord-Trøndelag, and the Norwegian Prescription Database, including 15,017 women and 13,241 men aged 50–85 years. The study population was followed from the date of participating in HUNT3 (2006–2008) until the date of first fracture (forearm or hip), death, or end of study (31 December 2012). The Cox proportional hazards model with time-dependent exposure to PPIs was applied, and each individual was considered as unexposed until the first prescriptions was filled. To be included, the prescription of PPIs should minimum be equivalent to 90 defined daily doses (DDD) in the period. Individuals were defined as exposed until 6 months after end of drug supply.
The proportion of women and men using PPIs was 17.9% and 15.5%, respectively. During a median of 5.2 years follow-up, 266 women and 134 men had a first hip fracture and 662 women and 127 men, a first forearm fracture. The combined rate/1000 patient-years for forearm and hip fractures in women was 49.2 for users of PPIs compared with 64.1 among non-users; for men 18.6 and 19.8, respectively. The hazard ratios with 95% confidence interval for the first forearm or hip fracture among users of PPIs in the age-adjusted analysis were 0.82 (0.67–1.01) for women and 1.05 (0.72–1.52) for men. Adjusting for age, use of anti-osteoporotic drugs, and FRAX, the HR declined to 0.80 (0.65–0.98) in women and 1.00 (0.69–1.45) in men.
Use of PPIs was not associated with an increased risk of fractures.
KeywordsFracture General population studies HUNT Osteoporosis Proton pump inhibitors
The Nord-Trøndelag Health Study (The HUNT Study) is a collaboration between HUNT Research Centre (Faculty of Medicine, Norwegian University of Science and Technology
NTNU), Nord-Trøndelag County Council, Central Norway Health Authority, and the Norwegian Institute of Public Health.
MH received a post-doctoral fellowship grant from the Liaison Committee between the Central Norway Regional Health Authority (RHA) and the Norwegian University of Science and Technology (NTNU).
BA has institutional research contracts with UCB and Novartis with funds paid to the institutions.
US has received research grants from or served as a Principal Investigator in studies conducted by Amgen, Eli Lilly, Novartis, Merck, and Wyeth pharmaceuticals.
Compliance with ethical standards
Conflicts of interest
MH, SS, HM, AD, AJS, AL, ES, SF, and BS have no disclosures.
- 1.(2019) The Norwegian Prescription Database. The Norwegian Institute of Public Health. http://www.norpd.no/
- 4.U.S. Food & Drug Administration F FDA. https://www.fda.gov/drugs/DrugSafety/ucm199082.htm
- 5.Poly TN, Islam MM, Yang HC, Wu CC, Li YJ (2019) Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 30:103–114CrossRefGoogle Scholar
- 6.Zhou B, Huang Y, Li H, Sun W, Liu J (2016) Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 27:339–347CrossRefGoogle Scholar
- 10.Bahtiri E, Islami H, Hoxha R, Qorraj-Bytyqi H, Rexhepi S, Hoti K, Thaci K, Thaci S, Karakulak C (2016) Esomeprazole use is independently associated with significant reduction of BMD: 1-year prospective comparative safety study of four proton pump inhibitors. Journal of bone and mineral metabolism 34:571–579PubMedCrossRefPubMedCentralGoogle Scholar
- 12.Targownik LE, Leslie WD, Davison KS et al (2012) The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol 107:1361–1369PubMedPubMedCentralCrossRefGoogle Scholar
- 15.Lewis JR, Barre D, Zhu K, Ivey KL, Lim EM, Hughes J, Prince RL (2014) Long-term proton pump inhibitor therapy and falls and fractures in elderly women: a prospective cohort study. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 29:2489–2497CrossRefGoogle Scholar
- 19.Wright MJ, Sullivan RR, Gaffney-Stomberg E, Caseria DM, O'Brien KO, Proctor DD, Simpson CA, Kerstetter JE, Insogna KL (2010) Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 25:2205–2211CrossRefGoogle Scholar
- 33.Furu K (2008) Establishment of the nationwide Norwegian Prescription Database (NorPD)–new opportunities for research in pharmacoepidemiology in Norway. Norsk Epidemiologi:129–136Google Scholar
- 34.Krokstad S, Langhammer A, Hveem K, Holmen T, Midthjell K, Stene T, Bratberg G, Heggland J, Holmen J (2012) Cohort profile: the HUNT study, Norway. Int J EpidemiolGoogle Scholar
- 36.Hoff M, Meyer HE, Skurtveit S, Langhammer A, Sogaard AJ, Syversen U, Dhainaut A, Skovlund E, Abrahamsen B, Schei B (2017) Validation of FRAX and the impact of self-reported falls among elderly in a general population: the HUNT study, Norway. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USAGoogle Scholar
- 39.Blum MR, Bauer DC, Collet TH, Fink HA, Cappola AR, da Costa BR, Wirth CD, Peeters RP, Åsvold BO, den Elzen W, Luben RN, Imaizumi M, Bremner AP, Gogakos A, Eastell R, Kearney PM, Strotmeyer ES, Wallace ER, Hoff M, Ceresini G, Rivadeneira F, Uitterlinden AG, Stott DJ, Westendorp RG, Khaw KT, Langhammer A, Ferrucci L, Gussekloo J, Williams GR, Walsh JP, Jüni P, Aujesky D, Rodondi N, Thyroid Studies Collaboration (2015) Subclinical thyroid dysfunction and fracture risk: a meta-analysis. JAMA 313:2055–2065PubMedPubMedCentralCrossRefGoogle Scholar
- 40.WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignement. Norway: Oslo. https://www.whocc.no/atc_ddd_index/
- 44.Dadwal G, Schulte-Huxel T, Kolb G (2019) Effect of antithrombotic drugs on bone health. Zeitschrift fur Gerontologie und GeriatrieGoogle Scholar
- 46.Carbone LD, Tylavsky FA, Cauley JA, Harris TB, Lang TF, Bauer DC, Barrow KD, Kritchevsky SB (2003) Association between bone mineral density and the use of nonsteroidal anti-inflammatory drugs and aspirin: impact of cyclooxygenase selectivity. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 18:1795–1802CrossRefGoogle Scholar